BenzingaBenzinga Japan
BenzingaBenzinga Japan
BenzingaBenzinga Japan
土曜日, 9 26

Cabaletta Bio Inc

CABANASDAQ
Trade with Public
Trade with Public
$2.07
-0.085-3.94%
近くで: Sep 25, 5:00 PM EST
$2.13
0.05712.76%
時間外: 6:59 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Cabaletta Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cabaletta Bio (CABA).

Price Target Range — 12 Quarters

Analyst Consensus — 9 Analysts

8Buy
1Hold
Consensus RatingBuy# Analysts9Avg. Consensus PT$20Upside to Avg. PT+836.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →
DateFirmAnalystActionRating ChangePrice Target
Sep 1, 2026HC Wainwright & Co.Douglas TsaoMaintainedBuy$16
Aug 14, 2026Wells FargoDerek ArchilaPT CutEqual-Weight$4→$3
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $16 price target.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from $4 to $3.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Raises Price Target to $4

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and raises the price target from $2 to $4.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $30 Price Target

Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $30 price target.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $13

Morgan Stanley analyst Michael Ulz maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lowers the price target from $14 to $13.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Cabaletta Bio, Raises Price Target to $16

Guggenheim analyst Yatin Suneja maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $15 to $16.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

BenzingaBenzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved